Research programme: mTOR inhibitors - OSI Pharmaceuticals
Alternative Names: OXA-01Latest Information Update: 16 Jul 2016
At a glance
- Originator OSI Pharmaceuticals
- Class Pyrazines; Small molecules
- Mechanism of Action MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 09 Jun 2010 OSI Pharmaceuticals has been acquired by Astellas Pharma
- 24 Oct 2008 Preclinical pharmacodynamics data presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008)